Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists ; volume:38 ; number:6 ; day:11 ; month:5 ; year:2021 ; pages:2821-2839 ; date:6.2021
Advances in therapy ; 38, Heft 6 (11.5.2021), 2821-2839, 6.2021
- Creator
-
Ard, Jamy
Fitch, Angela
Fruh, Sharon
Herman, Lawrence
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01710-0
- URN
-
urn:nbn:de:101:1-2021100218581045789881
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ard, Jamy
- Fitch, Angela
- Fruh, Sharon
- Herman, Lawrence
- SpringerLink (Online service)
Other Objects (12)
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes